Analysts of BKS recommend to pay attention to Gazprom Neft, and experts of ITI Capital advise to purchase of a share of Johnson & Johnson of the Photo: depositphotos.com ended Last week with strengthening of ruble and increase in prices for oil. Since the beginning of year Brent crude oil shows impressive growth — in a ruble equivalent of 26.7%. And it positively affected the quotations of papers of the oil and gas sector. Here only Gazprom Neft lags behind. Drew the attention of analytics of BKS to this factor and recommend to buy these papers. Potential — a little more than 5.5%. In case after all it is given effect to tough sanctions which are discussed in the USA, Gazprom Neft in a risk zone though results of the company interesting, the investment banker, the president of WhiteStone financial group Alexander Prosviryakov says. Alexander Prosviryakov is an investment banker, the president of WhiteStone financial group "Foreign investors do not love this paper just because of a binding to Gazprom, state corporation. And as separate business it is good. Oil it is rather high in comparison with the last two-three months now. Considering that, most likely, the dollar to ruble will rise in price by the end of the year, the return process in connection with payment of an external debt and other factors will begin now that will affect that the company will generate more revenues in rubles at the same even prices of oil therefore, perhaps, it makes sense it in a portfolio to have. It is better to wait when there is a sag caused by sanctions or some else factors". The ruble for last week rose against dollar and euro again, and those who adheres to the forecast that by the end of the year currencies can restore the positions should pay attention to investments in currency. Analysts of ITI Capital recommend for purchase of a share of Johnson & Johnson, growth potential — 8%. The company got approval of the American analog of Rospotrebnadzor of FDA on nasal spray for treatment of a depression recently. Analysts consider, that the annual sales volume of medicine can reach 3 billion dollars that, certainly, will affect financial performance of the company positively and will attract investors. The quarterly report which will appear on April 16 can stimulate quotations. One more plus: the company pays a dividend around 3% in dollars. It is unlikely the investor will earn on such paper much, but, most likely, strongly and will not lose, the portfolio manager Alexander Krapivko considers. Alexander Krapivko the portfolio manager "Fears of recession which, naturally, are projected on the sector of consumer goods will influence somehow this sector, but, I think, a lot of things already in the price. Analysts very strongly lowered the expected prices and lowered forecasts for profits of the company for the I quarter. Therefore it seems to me that the investor who will invest in this action both will a little win, and will a little lose. This nasal spray — one of hundreds of products which are offered by Johnson & Johnson. To stake on the fact that it will raise the quotations of this action I would not become. Probably, the sector will be at the level of the market or is slightly lower therefore
Eskrou of the first floor
Date: 2019-04-19 16:004 days ago
How will commercial rooms in new buildings after July 1 when housing construction passes to bank project financing be on sale? Photo: depositphotos.com Since July 1 in the market of housing constructi...
View details »
Instagram will hide quantity of likes?
Date: 2019-04-21 17:002 days ago
According to unconfirmed information, in the company test such opportunity in hope that users will be focused on quality of the posts, but not on quantity of likes of the Photo: Zuma\TASS Instagram te...
View details »